EST GeneDx (WGS) down 3% after Grizzly Research publishes short report, alleging fraudMaximize Your Portfolio with Data Driven ...
BTIG analysts stood firm on their positive stance towards GeneDx (NASDAQ:WGS), reiterating a Buy rating and a $95.00 price target for the company's stock. With analyst targets ranging from $70 to $118 ...
These contributions, added to GeneDx’s years of dedicated research efforts, influenced the broadening of phenotypes, the discovery of new disease mechanisms and new modes of inheritance ...
According to U.S.-based Grizzly Research LLC, many of the company’s European solar projects appear not to exist. Renesola has said it will review the report and address the key inaccuracies with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results